The FDA is coming down on yet another therapy over concerns about glass particulates winding up in drug solution. Regulators have slapped a clinical hold on 10 trials studying injectable versions of…
Another bad week for Biogen and its Tokyo-based partners at Eisai was extended on Wednesday with news that a panel review of their controversial Alzheimer’s drug aducanumab earned a pushback from the…
A Salt Lake City-based biotech startup is jumping on board the antibody train — and it’s equipping itself for the journey ahead with a round of VC financing. Sorriso Pharmaceuticals announced this…
Targeting overactive white blood cells known as eosinophils has become a hot drug target with multiple approvals in recent years. One company with big platform hopes targeting those cells has now…
Boston-based startup DermBiont has gone back to the venture well while tacking on another small buyout to swell the clinical pipeline. The startup, which raised an $8 million launch round in the…
As is the case with nearly any biomedical endeavor, the inability to easily peek into the body’s inner workings severely stymies research. While progress has been made in cancer and other diseases,…
Takeda CEO Christophe Weber thought he had a win in the bag for TAK-721 — one of the experimental drugs spotlighted in the company’s $62 billion Shire acquisition — and went so far as to announce a…
Over the last 20 years, ViaCyte — under one name or another — has pursued one of the most audacious
In a stunning climax to an eye-catching saga, Harvard scientist Charles Lieber has been convicted of
Christmas is coming early for Gyroscope. In its latest gene therapy gambit, Novartis is paying $800 million upfront to acquire the Syncona-backed biotech, with another $700 million reserved for…
